Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1993-8-9
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0171-5216
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
119
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
511-2
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8325902-Antineoplastic Agents,
pubmed-meshheading:8325902-Carboplatin,
pubmed-meshheading:8325902-Cisplatin,
pubmed-meshheading:8325902-Dose-Response Relationship, Drug,
pubmed-meshheading:8325902-Female,
pubmed-meshheading:8325902-Humans,
pubmed-meshheading:8325902-Organoplatinum Compounds,
pubmed-meshheading:8325902-Ovarian Neoplasms,
pubmed-meshheading:8325902-Randomized Controlled Trials as Topic
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
The role of platinum dose intensity in the management of ovarian cancer.
|
| pubmed:publicationType |
Editorial
|